TamRx Launches to Develop Pipeline of Immuno-oncology Products for Treatment of Cancers

BioMotiv and researchers from Rutgers, The State University of New Jersey, today announced the formation of a new biotech start-up, TamRx. The new company will focus on the development of a novel family of small molecule inhibitors designed to block tumor growth and stimulate the immune system to fight various forms of cancer.

Read More